Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Immunocompromised
IsoPlexis joins MediMergent, CCBD for COVID-19 study
The large multisite study will focus on the functionality of immune cells and their role in prevention of breakthrough COVID-19 infections in immunocompromised patients following administration of AstraZeneca's AZD7442 IM or IV antibody combination.
September 5, 2022
CoVac-1 vaccine shows promise for immunocompromised patients
Walz's team used their expertise with cancer therapeutics to develop a vaccine that induces T cells in immunocompromised patients who do not produce an adequate immune response to other vaccines.
May 1, 2022
Karius raises $165M for infectious disease blood test
The Redwood City, CA-based company markets the Karius test, a next-generation sequencing and artificial intelligence-powered option designed to screen blood for 1,000 pathogens, including bacteria, fungi, DNA viruses, and parasites. The test is being positioned for a range of applications, including complicated pneumonia, infections in immunocompromised patients, and endocarditis.
February 24, 2020
Roche launches adenovirus PCR test in Europe
Transplant patients are immunocompromised and at risk for developing infections, including from adenoviruses. Adenoviruses can lead to a range of conditions -- such as conjunctivitis, gastroenteritis, hepatitis, and pneumonia -- that cause complications and organ rejection in transplant patients.
January 14, 2020
Most Popular
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Chembio CEO urges stockholders to tender remaining shares as deadline is extended for acquisition
Cue Health Q4 revenues decline 24% as firm expands, diversifies POC test menu
Page 1 of 1